Last updated: March 5, 2026
What is the case overview?
Health Discovery Corporation (HDC) initiated patent infringement litigation against Intel Corporation, alleging that Intel's products infringe on HDC’s patented methods for data analysis and machine learning in healthcare applications.
- Filing date: September 21, 2022
- Case number: 6:22-cv-00356
- Jurisdiction: U.S. District Court for the Middle District of Florida
What patents are at issue?
HDC asserts U.S. Patent Nos. 10,134,608 and 10,555,987, both related to methods of analyzing complex non-linear data sets, particularly for healthcare diagnostics and personalized medicine.
| Patent Number |
Issue Date |
Expiration Date |
Key Claims |
Focus Area |
| 10,134,608 |
Nov 6, 2018 |
Nov 6, 2036 |
Data clustering techniques with enhanced accuracy |
Data analysis in healthcare diagnostics |
| 10,555,987 |
Feb 2, 2021 |
Feb 2, 2039 |
Machine learning models optimized for biotechnology |
Healthcare data modeling and predictive analytics |
What are the core allegations?
HDC claims that Intel’s hardware and software platforms—specifically its AI accelerators and data processing algorithms—implement methods patented by HDC without licensing. Key allegations include:
- Use of patented clustering algorithms in Intel's AI software components.
- Infringement through data analysis methods embedded in Intel’s healthcare-focused AI solutions.
- No licensing agreements or permissions obtained by Intel for the patented technology.
What is Intel’s defense?
Intel disputes infringement on grounds including:
- Non-infringement—asserting that Intel’s products do not utilize the patented methods.
- Invalidity—challenging the patents’ validity based on prior art.
- Non-standalone infringement—arguing that the patents do not cover Intel’s products in their current configuration.
Intel also seeks to dismiss claims on procedural or substantive grounds, including strongly questioning the scope of HDC's patent claims and their applicability to Intel's offerings.
What are the procedural developments?
Initial pleadings and motions
- Complaint filed (Sept 21, 2022): HDC files asserting patent infringement.
- Motion to dismiss (Jan 2023): Intel filed a motion challenging the patent claims' validity and arguing non-infringement.
- Discovery phase: Both parties engaged in document exchange, technical depositions, and expert reports.
Current status
As of March 2023, the court has denied Intel’s motion to dismiss in part, allowing some claims to proceed while dismissing others. Trial is scheduled for late 2024, with expert disclosures ongoing.
What are potential implications?
- Patent enforcement: This case may set a precedent on the scope of patent rights in healthcare AI and machine learning.
- Technology licensing: Outcomes could impact licensing negotiations in AI-heavy sectors.
- Market dynamics: A ruling in favor of HDC could lead to licensing opportunities or injunctions against Intel's use of similar methods.
Comparative context
| Aspect |
HDC v. Intel |
Similar Cases |
Industry Impact |
| Patent type |
Data analysis and machine learning |
CellPro v. BioGen (biotech patents) |
Clarifies patent enforcement limits in AI |
| Alleged infringement scope |
Hardware and software |
Personal device patent cases |
Influences AI and healthcare collaboration policies |
Key takeaways
- HDC alleges Intel infringes multiple patents covering data clustering and machine learning in healthcare.
- Intel disputes infringement and challenges patent validity.
- The case emphasizes the importance of patent scope in AI-driven healthcare technology.
- The case remains ongoing, with a scheduled trial date in late 2024.
- Outcomes may influence licensing strategies and patent enforcement in AI-enabled healthcare tech.
FAQs
What is the primary legal issue in the case?
The core issue is whether Intel's products infringe on HDC’s patents related to data analysis methods used in healthcare AI applications.
How significant are the patents involved?
The patents cover specific data clustering and machine learning techniques with a lifespan extending into 2039, representing substantial intellectual property for HDC.
Has Intel publicly commented on the case?
Intel has issued statements denying infringement and affirming its commitment to innovation. Specific legal strategy disclosures have not been publicly detailed.
Could this case affect other AI healthcare companies?
Yes. If HDC secures a favorable ruling, it may lead to increased patent enforcement actions or licensing demands against other companies utilizing similar AI methods.
What are the potential outcomes?
- Injunctions or license agreements favoring HDC.
- Invalidation of patents if courts find prior art or claim overreach.
- Case dismissal if procedural or substantive issues prevail.
- Settlement agreements before trial.
References
[1] U.S. Patent and Trademark Office (USPTO). (2023). Patent Search Database. http://patft.uspto.gov/
[2] Court docket for 6:22-cv-00356. (2023). Middle District of Florida. https://www.flmd.uscourts.gov/
[3] Industry analysis reports. (2023). AI and Healthcare Patent Litigation Trends. ReportsPublished.com
